Skip to main content

Table 6 Cost effectiveness analysis over 5-year treatment duration

From: The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia

Therapy Cost/patient (US$) QALYs gained/patient ICER (ΔC/ΔE) Comparator
Celecoxib + PPI 6,705.80 2.68 2,502.16 No treatment
Ibuprofen + PPI* 7,008.80 2.31 Dominated -
Celecoxib* 7,407.10 2.50 Dominated -
Diclofenac + PPI* 7,930.50 2.39 Dominated -
Diclofenac* 10,140.20 2.05 Dominated -
Ibuprofen* 10,586.10 1.83 Dominated -
Etoricoxib + PPI 11,574.20 2.64 Dominated -
Etoricoxib 12,983.90 2.48 Dominated -
  1. *Simple dominance: Another option is less expensive and more effective
  2. ICER, incremental cost-effectiveness ratio; PPI, proton-pump inhibitor; QALY, quality-adjusted life year
  3. ICER: additional cost per patient achieving a unit of effectiveness compared with the next less costly, non-dominated option